x
ServiziMenu principaleHome
You are here: Home > What we do > Future Events > Certificate of Advanced Studies in Lung cancer - second cohort (CASLu2)
Share Print

Certificate of Advanced Studies in Lung cancer - second cohort (CASLu2)

24.03.2021  -  26.05.2022

APPLICATION CLOSED

CERTIFICATE OF COMPETENCE

Description

Certificate of Competence in Lung cancer (CASLu) programme

Programme Chairs: Alessandra Curioni, CH; Enriqueta Felip, ES; Matthias Guckenberger, CH; Rolf Stahel, CH

The European School of Oncology (ESO) in cooperation with the University of Zurich has developed a post-graduate curriculum of studies designed for medical oncologists, radiation oncologists, thoracic surgeons, radiologists and pathologists, but it is equally accessible to graduates in natural sciences, who are engaged in the field of oncology, especially in the field of thoracic malignancies.

The objective of the programme is to advance the knowledge and science in the management of patients affected by lung cancer or other thoracic malignancies with a curriculum that extends over a period of 15 months and includes three seminars and four e-learning modules.

The programme is academically recognised with 14 European Credit Transfer and Accumulation System Points (ECTS) by the University of Zurich and upon successful completion, participants obtain an academic certificate and a diploma supplement issued by the University of Zurich.

The current CASLu cohort started in March 2021 and will conclude in May 2022. The subsequent cohort will run from 2023 to 2024. Admission to the programme is by competitive application only and is limited to 25 participants.

Programme

Block 1 - Virtual Seminar (+ ELCC)

CASLu2: Seminar 1

Block 2 - Online Module

CASLu2: Module 1: Epidemiology, prevention, biology & pathology of LC & other thoracic malignancies

Block 3 - Online Module

CASLu2: Module 2: Principles of lung cancer research

Block 4 - Virtual Seminar (+ESMO Congress)

CASLu2: Seminar 2

Block 5 - Online Module

CASLu2: Module 3: Principles of NSCLC diagnosis and treatment

Block 6 - Online Module

CASLu2: Module 4: Principles of treatment of SCLC, MPM, thymoma and thymic cancer

Block 7 - Zurich, Switzerland

CASLu2: Seminar 3

Faculty

Alfredo Addeo, Genèva, CH
Nicolaus Andratschke, University of Zurich Hospital, Department of Radiation Oncology, Zurich, CH
Paul Baas, The Netherlands Cancer Institute, Department of Thoracic Oncology, Amsterdam, NL
Dany Bell, Macmillan Cancer Support, Strategic Adviser Treatment, Medicines, Genomics Dept., London, UK
Sabina Berezowska, CHUV, Institute of Pathology, Lausanne, CH
Luca Bertolaccini, IEO, Istituto Europeo di Oncologia IRCCS, Thoracic Surgery Dpt., Milano, IT
Paolo Boffetta, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, US
Christian Britschgi, University Hospital Zurich, Dept. of Haematology and Oncology, Zurich, CH
Alessandro Brunelli, St. James University Hospital, Dept. of Thoracic Surgery, Leeds, UK
Lukas Bubendorf, Basel University Hospital, Dept. of Pathology, Basel, CH
Stefano Cafarotti, EOC - Ospedale Regionale Bellinzona e Valli, Thoracic Surgery Dpt., Bellinzona, CH
Raffaele Califano, The Christie NHS Foundation Trust, Dept. of Medical Oncology, Manchester, UK
Antonio Calles, University General Hospital Gregorio Maranon, Dept. of Thoracic Oncology, Madrid, ES
Emile Comans, Amsterdam UMC, Dept. of Nuclear Medicine, Amsterdam, NL
Alessandra Curioni-Fontecedro, Gattikon, CH
Urania Dafni, National and Kapodistrian University of Athens, Public Health Dpt., Goudi-Athens, GR
Sarah Danson, University of Sheffield, Academic Department of Clinical Oncology, Sheffield, UK
Joop de Langen, Netherlands Cancer Institute, Dept. of Thoracic Oncology, Amsterdam, NL
Dirk De Ruysscher, University Hospital Maastricht, Dept. of Radiotherapy, Maastricht, NL
Enriqueta Felip, Vall d'Hebron University Hospital, Dept. of Oncology, Barcelona, ES
John Field, The University of Liverpool Cancer Research Centre, Roy Castle Lung Cancer Research Programme, Liverpool, UK
Martin Filipits, Medical University of Vienna, Institute of Cancer Research, Vienna, AT
Tobias Finazzi, University Hospital Basel, Dept. of Radio-oncology, Basel, CH
Daniel Franzen, University of Zurich Hospital, Dept. of Pulmonology, Zurich, CH
Martin Früh, St. Gallen Cantonal Hospital, Dept. of Internal Medicine, St. Gallen, CH
Pilar Garrido Lopez, Ramon y Cajal University Hospital, Thoracic Tumor Unit, Madrid, ES
Oliver Gautschi, Lucerne Cantonal Hospital, Dept. of Medical Oncology, Lucerne, CH
Nicolas Girard, Institut Curie, ., Paris, FR
Ramaswamy Govindan, Washington University School of Medicine, Division of Oncology, St. Louis, MO, US
Francesco Grossi, UOC Oncologia Medica, Ospedale Maggiore Policlinico, Milan, IT
Matthias Guckenberger, University Hospital Zurich, Department of Radio-Oncology, Zürich, CH
Alexander Haragan, Royal Liverpool University Hospital, Dept. of Pathology, Liverpool, UK
Lizza Hendriks, Maastricht UMC+, Dept. of Pulmonary Diseases, Maastricht, NL
Anita Hiltbrunner, IBCSG/ETOP, Director, Bern, CH
Ilhan Inci, University of Zurich Hospital, Dept. of Thoracic Surgery, Zurich, CH
Markus Jörger, St. Gallen Cancer Centre, Dept of Medical Oncology and Clinical Pharmacology, St.Gallen, CH
Keith Kerr, Aberdeen University Medical School, Pathology Dept., Aberdeen, Scotland, UK
Olivia Lauk, University of Zurich Hospital, Dept. of Thoracic Surgery, Zurich, CH
Mitchell Levesque, University of Zurich Hospital, Faculty of Medicine, Dept. of Dermatology, Schlieren, CH
Alexander Louie, Sunnybrook Health Sciences Center, Dept. of Radiation Oncology, Toronto, CA
Ernest Nadal, Institut Català  d'Oncologia, Medical Oncology Department, L'Hospitalet (Barcelona), ES
Anastassia Negrouk, EORTC DPO, International Policy Office, Brussels, BE
Anouk Neven, EORTC Headquarters, Statistics Department, Brussels, BE
Andrew Nicholson, Royal Brompton Hospital, Histophatology Dept., London, UK
Nicola Normanno, ITN - IRCCS G. Pascale Foundation, Cell Biology and Biotherapy Unit, Napoli, IT
Emma O'Dowd, Nottingham City Hospital, Dept. of Epidemiology and Public Health, Nottingham, UK
Alexandros Papachristofilou, University Hospital Basel, Radiation Oncology Dpt., Basel, CH
Kostas Papagiannopoulos, St. James University Hospital, Dept. of Thoracic Surgery, Leeds, UK
Antonio Passaro, European Institute of Oncology IRCCS, Dept. of Thoracic Oncology, Milan, IT
Lorenzo Patocchi, Cryms, DEV, Lamone, CH
Aurel Perren, University of Bern, Institute of Pathology, Bern, CH
Solange Peters, University Hospital Center Vaudois, Oncology Dept., Lausanne, CH
Isabelle Schmitt-Opitz, University of Zurich Hospital, Dept. of Thoracic Surgery, Zurich, CH
Jean-Paul Sculier, Institut Jules Bordet, Dept. of Thoracic Oncology, Brussels, BE
Suresh Senan, VU University Medical Center, Dept. of Radiotherapy, Amsterdam, NL
Martin Sos, University Hospital Cologne, Molecular Pathology, Cologne, DE
Rolf A. Stahel, University Hospital Zurich, Comprehensive Cancer Center Zurich, Zurich, CH
Emily Stone, St. Vincent's Hospital, Dept. of Thoracic Medicine, Darlinghurst, AU
Erik Thunnissen, VUMC Amsterdam, Dept. of Pathology, Amsterdam, NL
Luzia Travado, Champalimaud Foundation, Champalimaud Centre For the Unknown, Lisbon, PT
Ming-Sound Tsao, Princess Margaret Cancer Centre, Ontario Cancer Institute, Toronto, CA
Samra Turajlic, The Francis Crick Institute, Turajlic Lab, London, UK
Alexandar Tzankov, Basel University Hospital, Institute of Pathology, Basel, CH
Maries van den Broek, Zurich, CH
Kazuhiro Yasufuku, Toronto General Hospital, Divistion of Thoracic Surgery, Toronto, ON, CA